Cerevance Media Center

Current News

April 19, 2022

Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.

READ FULL

March 31, 2022

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.

READ FULL

January 25, 2022

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

READ FULL

September 8, 2021

Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors

Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 16, 2023

Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

Date:
Tuesday, May 30, 2023
Time:
2:00pm – 4:00pm
Location:
Miami, Florida
Media:
Oral Presentation
Read full

May 9, 2023

Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

Date:
Monday, May 15, 2023
Time:
Check schedule for times
Location:
British Columbia, Canada
Media:
Presentation
Read full

May 8, 2023

2023 RBC Capital Markets Global Healthcare Conference

Date:
Tuesday, May 16, 2023
Time:
9:00 – 9:25am ET
Location:
New York, NY
Media:
Presentation
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

August 14, 2023

A Covalent Binding Mode of a Pyrazole-Based CD38 Inhibitor

Doyle, K., Roberts, M., Harvey, J, Hewer, R., Zebisch, M., Rangel, V., Gu, M., Wu, Y., Yang, L., Carlton, M., Dawson, L. & Bürli, R.

Viewview

October 15, 2018

Species and Cell-Type Properties of Classically Defined Human and Rodent Neurons and Glia

Xu, X., Stoyanova, E.I., Lemiesz, A.E., Xing, J., Mash, D.C., Heintz, N.

Viewview